What’s New at Capitainer – Lead, Thyroid & Alzheimer’s

From tackling lead testing challenges to enabling new thyroid testing services with Life Genomics, and exploring Alzheimer’s screening – there’s plenty happening at Capitainer this September. Scroll down for the latest updates!

Webinar: Advancing Lead Testing – From Challenges to Solutions

September 30, 2025

Lead exposure remains a pressing public health issue in the U.S., and laboratories play a key role in providing reliable testing. In this webinar, we will explore the main challenges in lead testing and highlight practical solutions for labs. You’ll also be introduced to miQro Lab Solutions and hear a real-world example of how Capitainer technology is applied in practice for lead testing.

Speakers

Dr. Donald Chace – Laboratory Director & Principal Scientist, Capitainer. Over 30 years of experience in dried blood spot testing and mass spectrometry; developer of the tandem MS method used worldwide in newborn screening.

Dr. Nesta Bortey-Sam – Assistant Professor, Environmental & Occupational Health, University of Pittsburgh. Chemist and toxicologist with nearly 20 years of research on lead exposure and metal toxicology globally.

Moderated by Ingrid Lyttkens, Marketing Manager, Capitainer.

Agenda

Introduction
Lead exposure in the U.S.
Challenges & Solutions
miQro Lab Solutions
Use Case
Q&A

Capitainer in Norway: Health2B Fagdag

This week, our Senior Product Specialist, Gang, visited the Health2B Fagdag Metabolomikk conference in Oslo: “Partnership for precision medicine and value creation.” She also had the chance to meet Ida, who is carrying out her master’s thesis at UiO and Oslo University Hospital.

We’re proud to see Capitainer’s microsampling cards being used in innovative research projects like Ida’s – exploring how self-sampling can open new possibilities in metabolomics and lipidomics, while supporting the shift toward decentralized healthcare.

TSH Self-Sampling: Ready for Launch

Last year, we announced our collaboration with Life Genomics to make high-quality home sampling available for thyroid health.

Now, we’re pleased to share that the service is ready to launch on October 1 – individuals across Sweden will be able to screen for hypothyroidism conveniently from home, with TSH samples analyzed at Life Genomics’ accredited laboratory in Gothenburg.

This is an important step toward improving early detection of thyroid dysfunction – helping identify individuals with previously undiagnosed hypothyroidism and supporting healthcare systems in creating more sustainable workflows.

Blog post: Screen for early detection?

Screen for early detection?

🧠 Alzheimer’s disease (AD) is the leading cause of dementia, accounting for 60–80% of all cases. One of the most striking discoveries in Alzheimer’s research is that the disease begins silently decades before symptoms, with amyloid and tau accumulation starting 20 years or more before memory loss or confusion.

Blood-based biomarkers such as p-tau217 have shown strong potential for detecting early signs of AD – opening new possibilities for earlier, more accessible screening.

So if screening is possible, why don’t we do it? Read more about this in our latest blog post.

Stay Connected

And between us- let’s just say a little bird told us that an Alzheimer’s-focused webinar may be coming soon… 🐦